Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade findings of the ESPRIT trial

Circulation: Cardiovascular Interventions

Volumn 2, Issue 1, 2009, Pages 43-51

  Tcheng, James E ^a   Lim, Ing Haan ^b   Srinivasan, Shankar ^c   Jozic, Joseph ^d   Gibson, C Michael ^e   O'Shea, J Conor ^f   Puma, Joseph A ^g   Simon, Daniel I ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BON SECOURS HOSPITAL   (Ireland)

^g LENOX HILL HOSPITAL   (United States)

Author keywords

Angioplasty; Coronary disease; Platelets; Risk factors; Stents

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; INTEGRIN;

ADULT; ARTICLE; BARE METAL STENT; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; CORONARY STENT; CORONARY STENT DIAMETER; CORONARY STENT LENGTH; CORRELATION ANALYSIS; DEATH; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARAMETER; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; THROMBOSIS PREVENTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; STENTS; THROMBOSIS; TREATMENT OUTCOME;

EID: 74049114096     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.108.809285     Document Type: Article

References (18)

1. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III, Morrison DA, O'Neil WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/ AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:e166-e286.
2. King SB III, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008;51:172-209.
3. Budde T, Haude M, Hopp HW, Kerber S, Caspari G, Fassbender G, Fingerhut M, Novopashenny I, Ogurol Y, Breithardt G, Erbel R, Erdmann E, Wischnewsky MB. A prognostic computer model to individually predict post-procedural complications in interventional cardiology: the INTERVENT Project. Eur Heart J. 1999;20:354-363.
4. Harrell L, Schunkert H, Palacios IF. Risk predictors in patients scheduled for percutaneous coronary revascularization. Catheter Cardiovasc Interv. 1999;48:253-260.
5. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schuhlen H, Dirschinger J, Berger PB, Schomig A, ISAR-REACT 2 Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006;295:1531-1538.
6. Krone RJ, Shaw RE, Klein LW, Block PC, Anderson HV, Weintraub WS, Brindis RG, McKay CR; ACC-National Cardiovascular Data Registry. Evaluation of the American College of Cardiology/American Heart Association and the Society for Coronary Angiography and Interventions lesion classification system in the current "stent era" of coronary interventions (from the ACC-National Cardiovascular Data Registry). Am J Cardiol. 2003;92:389-394.
7. Ross MJ, Herrmann HC, Moliterno DJ, Blankenship JC, Demopoulos L, DiBattiste PM, Ellis SG, Ghazzal Z, Martin JL, White J, Topol EJ. Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. J Am Coll Cardiol. 2003;42:981-988.
8. Blankenship JC, Tasissa G, O'Shea JC, Iliadis EA, Bachour FA, Cohen DJ, Lui HK, Mann T, Cohen E, Tcheng JE; ESPRIT Investigators. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT Trial. J Am Coll Cardiol. 2001;38:653-658.
9. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, van Dick N, Russell ME, Mohr FW, Serruys PW. The Syntax score: an angiographic tool grading the complexity of coronary artery disease. Eurointervention. 2005;1:219-227.
10. O'Shea JC, Madan M, Cantor WJ, Pacchiana CM, Greenberg S, Joseph DM, Kitt MM, Lorenz TJ, Tcheng JE. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention. Am Heart J. 2000;140:834-839.
11. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037-2044.
12. O'Shea JC, Buller CE, Cantor WJ, Chandler AB, Cohen EA, Cohen DJ, Gilchrist IC, Kleiman NS, Labinaz M, Madan M, Hafley GE, Califf RM, Kitt MM, Strony J, Tcheng JE; ESPRIT Investigators. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA. 2002;287:618-621.
13. Adabag AS, Rector T, Mithani S, Harmala J, Ward HB, Kelly RF, Nguyen JT, McFalls EO, Bloomfield HE. Prognostic significance of elevated cardiac troponin I after heart surgery. Ann Thorac Surg. 2007; 83:1744-1750.
14. Apple FS, Pearce LA, Chung A, Ler R, Murakami MM. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndromes. Clin Chem. 2007; 534:874-881.
15. Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Satler LF, Kent KM, Stone GW, Leon MB. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions. Intravascular ultrasound study of 2256 patients. Circulation. 2000;101:604-610.
16. Kereiakes DJ, Wang H, Popma JJ, Kuntz RE, Donohoe DJ, Schofer J, Schampaert E, Meier B, Leon MB, Moses JW. Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol. 2006;48:21-31.
17. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio V, Hall P, Popma JJ, Koglin J, Russell ME; TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294: 1215-1223.
18. Puma JA, Banko LT, Pieper KS, Sacchi TJ, O'Shea JC, Dery JP, Tcheng JE. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial. J Am Coll Cardiol. 2006;47:715-718.